Towards a Global Map of Epigenetic Variation
A new DNA map, published in Nature Genetics today, provides the first large-scale study of biological inheritance in human that is not DNA-sequence based. The map of human chromosomes 6, 20 and 22 shows that as many as one in six of our human genes might be subject to modifications that could alter their activity by epigenetic changes – under the influence of the environment. Understanding these modifications will be important in diagnosis, drug development and disease study.
The epigenome is the interface of genetics and environment, where plasticity of epigenetic changes modifies the hard wiring of our genetic code. Increasingly it is thought that at this interface lie clues to how lifestyle and the environment affect our susceptibility to many diseases.
Epigenetic changes include modification of DNA bases, through addition or removal of simple chemical tags, such as a methyl group, and similar changes of the proteins that are closely entwined with DNA to form chromatin, the functional form of the genome. Collectively, these modifications are also referred to as the ‘epigenetic code’ which researchers believe defines how different genetic programmes can be executed from the same genome in different tissues.
To examine how and where DNA modification might vary, the team from the Wellcome Trust Sanger Institute and Epigenomics AG measured levels of DNA methylation across three chromosomes in twelve different tissues. The results, from almost two million measurements, looked for differences between tissues as well as differences that might be linked to age or sex.
Although DNA methylation can vary over a wide dynamic range, the study revealed the majority of sites to have on/off status (e.g. being unmethylated or methylated) and identified distinct regions in the genome where methylation differs between tissues but no significant differences were found between two age groups – average age 26 years old and average age 68 years old. Age has been suspected to influence the plastic changes in methylation, and perhaps influence disease processes, but these remarkable results suggest methylation states are more stable than previously thought. The authors do emphasize that discrete changes may occur in regions or tissues not examined here.
Moreover, the two sexes showed indistinguishable patterns of methylation of regions not on the sex chromosomes, X and Y, or part of imprinted regions which are known to have parent-of-origin specific methylation patterns. Except for those regions, the global patterns of methylation are thus the same in males and females.
“There is much less noise in the system than we feared. Our data show DNA methylation to be stable, specific and essentially binary (that is, on or off) – all key hallmarks of informative clinical markers. Our conclusion is that epigenetic markers will be a powerful addition to the current repertoire of genetic markers for future disease association studies, particularly where non-genetic factors are known to play a role, for example in cancer, and where they are suspected, as in autoimmune disease.”
Dr Stephan Beck Project Leader at the Wellcome Trust Sanger Institute
Analysis of the global epigenetic landscape revealed methylation to be tissue- and cell-type specific with sperm showing the greatest difference (up to 20 per cent) when compared to other cell types, emphasizing the extensive epigenetic reprogramming during gametogenesis.
The team found that tissue-specific methylation of one in three genes they studied was associated with changed levels of gene activity. Intriguingly, tissue-specific differences were enriched in regions called evolutionary conserved regions (ECRs), lying distant from genes, out in the ‘junk’ DNA. ECRs were more often differentially methylated than regions close to genes, suggesting they might have an undiscovered role in gene or chromosome activity.
The study also looked at predicted genes that have decayed and appear to have lost function – so-called pseudogenes – or lack experimental verification. The control regions for almost 90 per cent were methylated, suggesting that methylation plays a role in silencing such genes and that many of the predicted genes might also be non-functional.
In 70 per cent of cases, the patterns of methylation were also conserved between mouse and human tissues. Less than 5 per cent differed to a great extent, supporting previous studies that suggest some epigenetic states to be conserved between these two species.
This stage of the HEP has defined the extent of methylation on a chromosomal scale and identified new possible roles for regions of the genome that we understand only poorly. But its importance goes beyond that.
“This is by far the most comprehensive study in understanding epigenetic differences. It is a breakthrough: we now have a sense of chromosome-wide epigenetics and this study shows what can be done to unravel this complex and clinically important process.
“The achievements serve to emphasize the need for genome-wide analysis of epigenetics – not only the study of methylation differences of DNA but also of chromatin changes. We know from individual studies that these changes are important in some diseases and we need now to establish a comprehensive study programme. The recently initiated international Alliance for Human Epigenomics and Disease (AHEAD) project by the American Association for Cancer Research can be expected to be invaluable for our understanding how genomes function and to take us toward a truly integrated (epi)genetic approach to common disease.”
Professor Peter Jones Director at the University of Southern California/Norris Comprehensive Cancer Center and a member of the Advisory Board of Epigenomics AG
More information
Websites
- Publication doi:10.1038/ng1909
- Human Epigenome Project – http://www.epigenome.org/
- Epigenome Network of Excellence – http://www.epigenome-noe.net/
- Epigenomics AG – http://www.epigenomics.com/
Publications:
Selected websites
The Wellcome Trust Sanger Institute
The Wellcome Trust Sanger Institute, which receives the majority of its funding from the Wellcome Trust, was founded in 1992. The Institute is responsible for the completion of the sequence of approximately one-third of the human genome as well as genomes of model organisms and more than 90 pathogen genomes. In October 2006, new funding was awarded by the Wellcome Trust to exploit the wealth of genome data now available to answer important questions about health and disease.
The Wellcome Trust and Its Founder
The Wellcome Trust is the most diverse biomedical research charity in the world, spending about £450 million every year both in the UK and internationally to support and promote research that will improve the health of humans and animals. The Trust was established under the will of Sir Henry Wellcome, and is funded from a private endowment, which is managed with long-term stability and growth in mind.
